Tdap Vaccination During Pregnancy Following Other Recent Tetanus-Containing Vaccine

Article

Among women who received the tetanus, diphtheria, and acellular pertussis (Tdap) vaccine during pregnancy, there was no increased risk of adverse events in the mothers or adverse birth outcomes in newborns for women who had received a tetanus-containing vaccine in the previous five years, according to a study in the Oct. 20 issue of JAMA.

Pertussis (whooping cough) is a vaccine-preventable illness that has been increasing in incidence over the past decade in the United States. Neonates and infants are at increased risk of pertussis-related hospitalization and death compared with older children and adults. The Advisory Committee on Immunization Practices recommends the Tdap vaccine for pregnant women during each pregnancy, regardless of prior immunization status. However, safety data on repeated Tdap vaccination in pregnancy has been lacking, according to background information in the article.

Lakshmi Sukumaran, MD, MPH, of the Centers for Disease Control and Prevention (CDC), and colleagues conducted a study that included 29,155 pregnant women, ages 14 through 49 years, using data from 2007 to 2013 from seven Vaccine Safety Datalink sites in California, Colorado, Minnesota, Oregon, Washington, and Wisconsin. The authors examined outcomes for women who received Tdap in pregnancy following a prior tetanus-containing vaccine less than 2 years before, two to five years before, and more than five years before.

The researchers found no significant differences in rates of acute adverse events in the mothers (fever, allergy, and local reactions) or adverse birth outcomes in neonates (small for gestational age, preterm delivery, and low birth weight) when comparing women who were vaccinated with Tdap during pregnancy regardless of the length of time since a prior tetanus-containing vaccine.

"Our findings should reassure patients and clinicians who might be hesitant to give Tdap vaccine to pregnant women who recently received a Tdap or other tetanus-containing vaccination," the authors write.

The researchers add that future studies are needed to determine if there are differences in other important adverse pregnancy outcomes, such as stillbirth and spontaneous abortion, when Tdap is given in pregnancy in close intervals from prior tetanus-containing vaccines.

Reference: Lakshmi Sukumaran, Natalie L. McCarthy, Elyse O. Kharbanda, Michael M. McNeil, Allison L. Naleway, Nicola P. Klein, Michael L. Jackson, Simon J. Hambidge, Marlene M. Lugg, Rongxia Li, Eric S. Weintraub, Robert A. Bednarczyk, Jennifer P. King, Frank DeStefano, Walter A. Orenstein, Saad B. Omer. Association of Tdap Vaccination With Acute Events and Adverse Birth Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations. JAMA, 2015; 314 (15): 1581 DOI: 10.1001/jama.2015.12790

Source: JAMA Network Journals

Recent Videos
Kevin Anderson, MBA, BS, CRCST, Senior Manager, Commercial Education Services, Heatlthmark, a Getinge Company
Damien Berg, BA, BS, CRCST, AAMIF, is the vice president of strategic initiatives for the HSPA.
Annet Adegboyega, DNP, MSN, BSN, RN, CNOR; Mihyun "Rose" Jang, MSN, MPH, BSN, RN, CNOR; and Renilda Tijones, MSN, BSN, RN, CNOR.
Roundtable of Vet IPs (Adobe Stock)
APIC 2025 President Carol McLay, DrPH, MPH, RN, CIC FAPIC   (Image credit: APIC)
Paulo J. M. Brois, DVM, MSN, RN; Luisa M. P. Soares, RN; and Teresa A. Santos, RN, at #AORN2025
Michael Sinnott, MBBS, FACEM, FRACP, at 2025 AORN Global Conference & Expo.
Roundtable of Vet IPs
Meet Marjorie Wall, EDBA, CRCST, CIS, CHL, CSSBB.
Related Content